Please assess the completion status of the following clinical trial:

Trial Title: Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Requires IV antibiotic therapy with diagnosis of ventilated nosocomial pneumonia~* Gram-positive bacteria on respiratory Gram stain~Exclusion Criteria:~* Pneumonia of community, viral, fungal or parasitic etiology~* Structural lung abnormalities~* Immunosuppression~* Previous antibiotics for \> 24 hours~* Expected survival of \< 72 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tedizolid phosphate IV (Type: EXPERIMENTAL): Ventilated HABP/VABP participants receive tedizolid phosphate 200 mg IV once daily for 7 days, or for 14 days for concurrent bacteremia.
- Linezolid IV (Type: ACTIVE_COMPARATOR): Ventilated HABP/VABP participants receive linezolid 600 mg IV every 12 hours for 10 days, or for 14 days for concurrent bacteremia.

Based on this trial design, predict the completion outcome and termination type (if applicable).